Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Research supports that iron dysregulation may drive AMD | Ophthalmology Times
Image credit: AdobeStock/Gorodenkoff A new study supports the hypothesis that iron dysregulation may be a driver of dry age-related macular degeneration (AMD). This could be especially true in the early stage of geographic atrophy (GA). According to the research, the…
ONL Therapeutics randomizes first patient in phase 2 GALAXY trial evaluating xelafaslatide | Ophthalmology Times
(Image Credit: AdobeStock/Kirsten D) ONL Therapeutics announced the first patient has been randomized in its phase 2 GALAXY (NCT06659445) trial evaluating xelafaslatide (formerly ONL1204) in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD). According to the…
Advancements in femtosecond laser technology benefit surgeons and patients | Ophthalmology Times
(Image Credit: AdobeStock/Wirestock) The field of refractive surgery has undergone multiple technological developments aimed at enhancing patient outcomes, optimizing workflows, and improving patient satisfaction. The VisuMax laser platform (Zeiss) is among the commercially available femtosecond laser systems and is used…
What if? Ophthalmology without OCT – Part 1 | Ophthalmology Times
In celebration of Ophthalmology Times‘ 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented. Video Transcript: Editor’s note: The below…
ICYMI: AAO 2025 showcases new technologies and continued research | Ophthalmology Times
Image credit: AdobeStock/zimmytws The annual scientific meeting of the American Academy of Ophthalmology (AAO) was held in Orlando, Florida. At this meeting, presenters and companies highlighted new technologies and continued areas of research. Ophthalmology Times is highlighting some stories that…
Throwback Series: Managing bilateral diabetic macular edema early in practice | Ophthalmology Times
In celebration of Ophthalmology Times’ 50th anniversary, leaders revisit a memorable “throwback” case from earlier in their careers. In this special series, they reflect on how evolving knowledge, techniques, and technologies have transformed the way such cases are managed today.…
Evolving glaucoma therapy: A new era of interventional strategies | Ophthalmology Times
(Image Credit: AdobeStock/Yakobchuk Olena) Inder Paul Singh, MD, from The Eye Centers of Racine and Kenosha, Wisconsin, recently moderated an Ophthalmology Times Case-Based Roundtable that addressed the new playing field in glaucoma care. For Singh, the term interventional glaucoma no…
Proactive strategies and sustained delivery advance glaucoma care | Ophthalmology Times
(Image Credit: AdobeStock/Monkey Business) Proactive strategies in glaucoma care, including minimally invasive glaucoma surgery (MIGS) and physician decision-making, were the focus of a recent Ophthalmology Times Case-Based Roundtable, moderated by Sahar Bedrood, MD, PhD, a glaucoma specialist at Advanced Vision…
Novel therapy for incision-free keratoconus: Q&A with Gloria B. Chiu, OD, FAAO, FSLS | Ophthalmology Times
The FDA-approved, incision-free Epioxa therapy is changing the landscape of keratoconus care, explains Gloria B. Chiu, OD, FAAO, FSLS. (Image credit: AdobeStock/Zarina Lukash) Glaukos recently obtained FDA clearance for Epioxa, a topical, incision-free therapy for keratoconus that preserves the corneal epithelium.1 The…
Nanoscope Therapeutics releases positive 3-year follow-up data from REMAIN study | Ophthalmology Times
(Image Credit: AdobeStock/Minerva Studio) Nanoscope Therapeutics has released positive 3-year follow-up data from its REMAIN study, the long-term extension of the phase 2b/3 RESTORE trial (NCT04945772) evaluating MCO-010 in retinitis pigmentosa (RP). RESTORE was a multicenter, randomized, double-masked, sham-controlled, dose-ranging study evaluating 2 dose…